Maraviroc (MVC) is a CCR5 coreceptor antagonist indicated in combination with other antiretroviral agents for the treatment of CCR5-tropic human immunodefinciency virus-1 infection. In this study, the metabolism of MVC was investigated in human liver microsomes to delineate the relative roles of CYP3A4 and CYP3A5. MVC is metabolized to five hydroxylated metabolites, all of which were biosynthesized
Maraviroc(M
VC)是一种CCR5共受体拮抗剂,与其他抗逆转录病毒药物联合使用可治疗CCR5嗜性人免疫缺陷病毒1感染。在这项研究中,研究了人肝微粒体中M
VC的代谢,以描绘CYP3A4和CYP3A5的相对作用。M
VC被代谢为五种羟基化代谢物,所有这些代谢物均已
生物合成,并使用质谱和NMR进行了鉴定。代谢的位点是4,4-二
氟环己基部分的2-和3-位和三唑部分的甲基。通过与真实标准进行比较,最终确定了绝对配置。使用CYP3cide(一种CYP3A4的选择性失活剂),将
生物合成的代谢物用于肝微粒体的定量体外实验。(1S,2S)-2-OH-M
VC是主要代谢物,约占总代谢的一半,CYP3A5在来自CYP3A5 * 1 / * 1供体的微粒体中对该途径的贡献约为40%。其他四种代谢物几乎全部被CYP3A4代谢。(1S,2S)-2-羟基化也与CYP3A5特异性活性T-5 N-氧化有关。这些数据与临